Vieweg J, Rosenthal F M, Bannerji R, Heston W D, Fair W R, Gansbacher B, Gilboa E
Urology Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Cancer Res. 1994 Apr 1;54(7):1760-5.
Adenocarcinoma of the prostate is the most common cancer in men. The majority of cancers are discovered once they have already metastasized, and there is no effective therapy for prostatic cancer at this stage. The use of cytokine-secreting tumor cell preparations as therapeutic vaccines for the treatment of advanced prostate cancer was investigated in the Dunning rat R3327-MatLyLu prostatic tumor model. IL-2 secreting, irradiated, tumor cell preparations were capable of curing animals with s.c. established tumors, and induced immunological memory that protected animals from subsequent tumor challenge. Immunotherapy was less effective when tumors were induced orthotopically, but nevertheless led to improved outcome, significantly delaying, and occasionally preventing, recurrence of tumors after resection of the cancerous prostate. Granulocyte-macrophage colony stimulating factor secreting tumor cell preparations were less effective, and interferon-gamma secreting cells had only a marginal effect. Induction of a potent immune response in tumor bearing animals against the nonimmunogenic MatLyLu tumor supports the view that active immunotherapy warrants further investigation as a potential therapeutic approach to prostate cancer.
前列腺腺癌是男性中最常见的癌症。大多数癌症在已经发生转移后才被发现，而在这个阶段没有有效的前列腺癌治疗方法。在邓宁大鼠R3327-MatLyLu前列腺肿瘤模型中，研究了使用分泌细胞因子的肿瘤细胞制剂作为治疗性疫苗来治疗晚期前列腺癌。分泌白细胞介素-2的经辐照的肿瘤细胞制剂能够治愈皮下已形成肿瘤的动物，并诱导免疫记忆，从而保护动物免受后续肿瘤攻击。当肿瘤原位诱导时，免疫疗法效果较差，但仍能改善预后，显著延迟并偶尔预防癌性前列腺切除术后肿瘤的复发。分泌粒细胞-巨噬细胞集落刺激因子的肿瘤细胞制剂效果较差，而分泌干扰素-γ的细胞仅有轻微作用。在荷瘤动物中诱导针对非免疫原性MatLyLu肿瘤的强效免疫反应，支持了主动免疫疗法作为前列腺癌潜在治疗方法值得进一步研究的观点。
